Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention ('The ELIMIT Trial')

Trial Profile

Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention ('The ELIMIT Trial')

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Ezetimibe (Primary) ; Niacin (Primary) ; Aspirin; Atorvastatin; Clopidogrel; Simvastatin
  • Indications Atherosclerosis
  • Focus Therapeutic Use
  • Acronyms ELIMIT Study
  • Most Recent Events

    • 11 Feb 2009 Planned end date changed from Jul 2010 to Aug 2010 as reported by ClinicalTrials.gov.
    • 26 Nov 2008 Status changed from recruiting to active, no longer recruiting as reported in ClinicalTrials.gov record.
    • 19 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top